190 related articles for article (PubMed ID: 30726838)
1. A Retrospective Review of Dupilumab for Hand Dermatitis.
Lee N; Chipalkatti N; Zancanaro P; Kachuk C; Dumont N; Rosmarin D
Dermatology; 2019; 235(3):187-188. PubMed ID: 30726838
[No Abstract] [Full Text] [Related]
2. Dupilumab: a milestone in the treatment of atopic dermatitis.
Tsianakas A; Ständer S
Lancet; 2016 Jan; 387(10013):4-5. PubMed ID: 26454359
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
[TBL] [Abstract][Full Text] [Related]
4. Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab.
Loman L; Diercks GFH; Schuttelaar MLA
Contact Dermatitis; 2021 Feb; 84(2):124-127. PubMed ID: 32864776
[No Abstract] [Full Text] [Related]
5. Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata.
Darrigade AS; Legrand A; Andreu N; Jacquemin C; Boniface K; Taïeb A; Seneschal J
Br J Dermatol; 2018 Aug; 179(2):534-536. PubMed ID: 29710431
[No Abstract] [Full Text] [Related]
6. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
Zimmermann M; Rind D; Chapman R; Kumar V; Kahn S; Carlson J
J Drugs Dermatol; 2018 Jul; 17(7):750-756. PubMed ID: 30005097
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab Treatment of Very Severe Refractory Atopic Hand Eczema.
Oosterhaven JAF; Romeijn GLE; Schuttelaar MLA
JAMA Dermatol; 2018 Aug; 154(8):969-970. PubMed ID: 29971331
[No Abstract] [Full Text] [Related]
8. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.
Wang FP; Tang XJ; Wei CQ; Xu LR; Mao H; Luo FM
J Dermatol Sci; 2018 May; 90(2):190-198. PubMed ID: 29472119
[TBL] [Abstract][Full Text] [Related]
9. IL-4Rα Inhibitor for Atopic Disease.
Chang HY; Nadeau KC
Cell; 2017 Jul; 170(2):222. PubMed ID: 28708993
[TBL] [Abstract][Full Text] [Related]
10. Long-term off-label dupilumab in pediatric atopic dermatitis: A case series.
Treister AD; Lio PA
Pediatr Dermatol; 2019 Jan; 36(1):85-88. PubMed ID: 30338546
[TBL] [Abstract][Full Text] [Related]
11. Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study.
Oosterhaven JAF; Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA
J Dermatol; 2019 Aug; 46(8):680-685. PubMed ID: 31187925
[TBL] [Abstract][Full Text] [Related]
12. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
[TBL] [Abstract][Full Text] [Related]
13. Addressing the immunopathogenesis of atopic dermatitis: advances in topical and systemic treatment.
Eichenfield LF; Stein Gold LF
Semin Cutan Med Surg; 2017 Mar; 36(2 Suppl 2):S45-S48. PubMed ID: 28654711
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis.
Maloney NJ; Tegtmeyer K; Zhao J; Worswick S
J Drugs Dermatol; 2019 Oct; 18(10):. PubMed ID: 31603635
[TBL] [Abstract][Full Text] [Related]
15. Development of Sézary syndrome following the administration of dupilumab.
Tran J; Morris L; Vu A; Duvic M
Dermatol Online J; 2020 Apr; 26(4):. PubMed ID: 32621690
[TBL] [Abstract][Full Text] [Related]
16. Hair Regrowth in a Patient With Long-standing Alopecia Totalis and Atopic Dermatitis Treated With Dupilumab.
Penzi LR; Yasuda M; Manatis-Lornell A; Hagigeorges D; Senna MM
JAMA Dermatol; 2018 Nov; 154(11):1358-1360. PubMed ID: 30304403
[No Abstract] [Full Text] [Related]
17. Rosacea associated with dupilumab therapy.
Heibel HD; Hendricks AJ; Foshee JP; Shi VY
J Dermatolog Treat; 2021 Feb; 32(1):114-116. PubMed ID: 31132923
[No Abstract] [Full Text] [Related]
18. Canalicular stenosis associated with dupilumab treatment for atopic dermatitis.
Loret L; Ninclaus V; Dendooven A; Lapeere H; Kreps EO
Eur J Dermatol; 2021 Dec; 31(6):843-844. PubMed ID: 34933837
[No Abstract] [Full Text] [Related]
19. Dupixent® (Dupilumab): A Newly Approved Interleukin-4 Receptor Antagonist for the Treatment of Atopic Dermatitis in Pediatric Patients.
Gupta AK; Love RP; Abramovits W; Vincent KD
Skinmed; 2019; 17(2):107-109. PubMed ID: 31145061
[No Abstract] [Full Text] [Related]
20. A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis.
Chipalkatti N; Lee N; Zancanaro P; Dumont N; Kachuk C; Rosmarin D
J Am Acad Dermatol; 2019 Apr; 80(4):1166-1167. PubMed ID: 30630024
[No Abstract] [Full Text] [Related]
[Next] [New Search]
